Pleura - Mesothelioma
In this phase three national, multicenter, UK randomized controlled trial, the authors seek to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone. The trial recruited patients between 2015 and 2021 from 26...
At the 2023 EACTS Annual Meeting, CTSNet Editor in Chief Joel Dunning and CTSNet senior editors set out to interview the most knowledgeable CT surgeons from around the world. Stay...
Malignant pleural mesothelioma is an aggressive tumor of the pleura. Extended pleurectomy and decortication is a lung sparing cytoreductive procedure used in the management of this disease for curative intent....
A recent study found that mesothelioma patients who undergo both lung-sparing extended pleurectomy and decortication can achieve extended survival compared to those who undergo just one type of surgery. When...
Patient Care and General Interest Despite being the leading cause of death in the US, heart disease was the most-Googled disease in only one state: Maine. A study that sought...
A useful editorial debating current issues on the classification of mesothelioma.
...Filmed at the 2018 STS Annual Meeting in Ft Lauderdale, FL, Joel Dunning of the James Cook University Hospital in London, UK, interviews Raja Flores of the Mount Sinai School...
Apostolos Nakas of the Glenfield Hospital in Leicester, UK, presents an overview of the surgical treatment of mesothelioma. Dr Nakas focuses on extended pleurectomy decortication, which is being evaluated in...
As many will recall, world chess champion Garry Kasparov was defeated by IBM’s Deep Blue computer in 1997. Now machine-learning algorithms have bested trained pathologists in differentiating between benign and...
In this single institution study, the prognostic role of soluble mesothelin-related peptides (SMRP) was evaluated in patients with pleural mesothelioma. Preoperative levels of SMRP were related to tumor volume and...
From one of the few relatively unbiased sources of information regarding surgical treatment of pleural mesothelioma, the authors describe populations of patients undergoing EPP or P/D and their outcomes. Survival...
We urgently need more answers for the patients affected by mesothelioma, a devastating diasese whose prognosis is 6-9 months from the diagnosis. We are now living the era of plateau...
Paul Van Schil of Antwerp University Hospital, Antwerp, Belgium, argues that surgery offers the best outcome for patients with mesothelioma. Dr. Van Schil reviews the evidence from surgical trials, noting...





